World Scientific
  • Search
  •   
Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×
Our website is made possible by displaying certain online content using javascript.
In order to view the full content, please disable your ad blocker or whitelist our website www.worldscientific.com.

System Upgrade on Tue, Oct 25th, 2022 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at [email protected] for any enquiries.

Research Progress and New Perspectives of Anticancer Effects of Emodin

    https://doi.org/10.1142/S0192415X23500787Cited by:0 (Source: Crossref)

    Emodin is a natural compound found in several traditional Chinese medicines, including Rheum palmatum and Polygonum cuspidatum. Recent studies have shown that emodin exhibits potent anticancer effects against a variety of cancer types, including liver, breast, lung, and colon cancer. Emodin’s anticancer effects are mediated through several mechanisms, including inhibition of cell proliferation, induction of apoptosis, and suppression of tumor angiogenesis and metastasis. In this review, we provide an overview of recent research progress and new perspectives on emodin’s anticancer effect. We summarize the current understanding of the molecular mechanisms underlying emodin’s anticancer activity, including its effects on signaling pathways such as the PI3K/Akt, MAPK, and NF-κB pathways. We also discuss the potential of emodin as a therapeutic agent for cancer treatment, including its use in combination with conventional chemotherapeutic drugs and as a sensitizer for radiotherapy. Furthermore, we highlight recent advances in the development of emodin derivatives and their potential as novel anticancer agents. Finally, we discuss the challenges and opportunities for the translation of emodin’s anticancer properties into clinical applications, including the need for further preclinical and clinical studies to evaluate its safety and efficacy. In conclusion, emodin represents a promising natural compound with potent anticancer properties, and its potential as a therapeutic agent for cancer treatment warrants further investigation. This review provides a comprehensive overview of the current research progress and new perspectives on emodin’s anticancer effects, which may facilitate the development of novel therapeutic strategies for cancer treatment.

    References

    • Abubakar, A.R. and M. Haque . Preparation of medicinal plants: Basic extraction and fractionation procedures for experimental purposes. J. Pharm. Bioallied. 12: 1–10, 2020. Crossref, Medline, ISIGoogle Scholar
    • Alam, M.S., A. Garg, F.H. Pottoo, M.K. Saifullah, A.I. Tareq, O. Manzoor, M. Mohsin and M.N. Javed . Gum ghatti mediated, one pot green synthesis of optimized gold nanoparticles: Investigation of process-variables impact using box-behnken based statistical design. Int. J. Biol. Macromol. 104: 758–767, 2017. Crossref, Medline, ISIGoogle Scholar
    • Albini, A., F. Tosetti, V.W. Li, D.M. Noonan and W.W. Li . Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol. 9: 498–509, 2012. Crossref, Medline, ISIGoogle Scholar
    • An, H., S. Lee, J.M. Lee, D.H. Jo, J. Kim, Y.S. Jeong, M.J. Heo, C.S. Cho, H. Choi, J.H. Seo, S. Hwang, J. Lim, T. Kim, H.O. Jun, J. Sim, C. Lim, J. Hur, J. Ahn, H.S. Kim, S.Y. Seo, Y. Na, S.H. Kim, J. Lee, J. Lee, S.J. Chung, Y.M. Kim, K.W. Kim, S.G. Kim, J.H. Kim and Y.G. Suh . Novel hypoxia-inducible factor 1α (HIF-1α) inhibitors for angiogenesis-related ocular diseases: discovery of a novel scaffold via ring-truncation strategy. J. Med. Chem. 61: 9266–9286, 2018. Crossref, Medline, ISIGoogle Scholar
    • An, S., S.J. Bing, J. Cho, K. Herath, A. Kim, H.W. Chang and Y. Jee . Emodin induces apoptosis of concanavalin a-stimulated murine splenocytes. Food. Biotechnol. 25: 1693–1700, 2016. Crossref, ISIGoogle Scholar
    • Ansari, M.A., I.M. Chung, G. Rajakumar, M.A. Alzohairy, M.N. Alomary, M. Thiruvengadam, F.H. Pottoo and N. Ahmad . Current nanoparticle approaches in nose to brain drug delivery and anticancer therapy — a review. Curr. Pharm. Des. 26: 1128–1137, 2020. Crossref, Medline, ISIGoogle Scholar
    • Baba, Y., T. Maeda, A. Suzuki, S. Takada, M. Fujii and Y. Kato . Deguelin potentiates apoptotic activity of an EGFR tyrosine kinase inhibitor (AG1478) in PIK3CA-mutated head and neck squamous cell carcinoma. Int. J. Mol. Sci. 18: 262, 2017. Crossref, Medline, ISIGoogle Scholar
    • Ban, E., S.H. An, B. Park, M. Park, N.E. Yoon, B.H. Jung and A. Kim . Improved solubility and oral absorption of emodin-nicotinamide cocrystal over emodin with PVP as a solubility enhancer and crystallization inhibitor. J. Pharm. Sci. 109: 3660–3667, 2020. Crossref, Medline, ISIGoogle Scholar
    • Ben-Neriah, Y and M. Karin . Inflammation meets cancer, with NF-κ B as the matchmaker. Nat. Immunol. 12: 715–723, 2011. Crossref, Medline, ISIGoogle Scholar
    • Berz, D and H. Wanebo . Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. J. Surg. Oncol. 103: 574–586, 2011. Crossref, Medline, ISIGoogle Scholar
    • Bhattacharjee, M., P. Upadhyay, S. Sarker, A. Basu, S. Das, A. Ghosh, S. Ghosh and A. Adhikary . Combinatorial therapy of thymoquinone and emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. Biochim. Biophys. Acta. Gen. Subj. 1864: 129695, 2020. Crossref, Medline, ISIGoogle Scholar
    • Braumann, C., G. Koplin, C. Geier, P. Höhn, J. Pohlenz, W. Dubiel and S. Rogalla . Dose-dependent role of novel agents emodin and BTB14431 in colonic cancer treatment in rats. Acta Chir. Belg. 117: 376–384, 2017. Crossref, Medline, ISIGoogle Scholar
    • Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6: 389–395, 2000. Crossref, Medline, ISIGoogle Scholar
    • Cha, T.L., L. Qiu, C.T. Chen, Y. Wen and M.C. Hung . Emodin downregulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res. 65: 2287–2295, 2005. Crossref, Medline, ISIGoogle Scholar
    • Cheema, S.K., A.S. Gobin, R. Rhea, G. Lopez-Berestein, R.A. Newman and A.B. Mathur . Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int. J. Pharm. 341: 221–229, 2007. Crossref, Medline, ISIGoogle Scholar
    • Chen, G., H. Qiu, S.D. Ke, S.M. Hu, S.Y. Yu and S.Q. Zou . Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling. World J. Gastroenterol. 19: 2481–2491, 2013. Crossref, Medline, ISIGoogle Scholar
    • Chen, P., Y. Liu, Y. Sun, C. Chen, Y. Qi and Y. Zhang . AZT and emodin exhibit synergistic growth-inhibitory effects on K562/ADM cells by inducing S phase cell cycle arrest and suppressing MDR1 mRNA/p-gp protein expression. Pharm. Biol. 51: 1586–1591, 2013. Crossref, Medline, ISIGoogle Scholar
    • Chen, H., W. Wei, Y. Guo, A. Liu, H. Tong, Z. Wang, W. Tan, J. Liu and S. Lin . Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol. Rep. 25: 1253–1261, 2011. Medline, ISIGoogle Scholar
    • Chen, R.S., J.Y. Jhan, Y.J. Su, W.T. Lee, C.M. Cheng, S.C. Ciou, S.T. Lin, S.M. Chuang, J.C. Ko and Y.W. Lin . Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp. Cell. Res. 315: 2658–2672, 2009. Crossref, Medline, ISIGoogle Scholar
    • Chen, X., Yang, R. Sun, Z. Mo, G. Jin, F. Wei, J. Hu, W. Guan, and N. Zhong . Preparation of lung-targeting, emodin-loaded polylactic acid microspheres and their properties. Int. J. Mol. Sci. 15: 6241–6251, 2014. Crossref, Medline, ISIGoogle Scholar
    • Chen, Y., J. Li, J. Hu, J. Zheng, Z. Zheng, T. Liu, Z. Lin and M. Lin . Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells. Int. J. Oncol. 45: 2076–2084, 2014. Crossref, Medline, ISIGoogle Scholar
    • Chen, Y., D. Gan, Q. Huang, X. Luo, D. Lin and J. Hu . Emodin and its combination with cytarabine induce apoptosis in resistant acute myeloid leukemia cells in vitro and in vivo. Cell. Physiol. Biochem. 48: 2061–2073, 2018. Crossref, MedlineGoogle Scholar
    • Chen, Y., X. Mei, D. Gan, Z. Wu, Y. Cao, M. Lin, N. Zhang, T. Yang, Y. Chen and J. Hu . Integration of bioinformatics and experiments to identify TP53 as a potential target in emodin inhibiting diffuse large B cell lymphoma. Biomed. Pharmacother. 107: 226–233, 2018. Crossref, Medline, ISIGoogle Scholar
    • Chen, Y., J. Zheng, D. Gan, Y. Chen, N. Zhang, Y. Chen, Z. Lin, W. Wang, H. Chen, D. Lin and J. Hu . E35 ablates acute leukemia stem and progenitor cells in vitro and in vivo. J. Cell. Physiol. 235: 8023–8034, 2020. Crossref, Medline, ISIGoogle Scholar
    • Chen, Y.C., S.C. Shen, W.R. Lee, F.L. Hsu, H.Y. Lin, C.H. Ko and S.W. Tseng . Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol. 64: 1713–1724, 2002. Crossref, Medline, ISIGoogle Scholar
    • Cho, B.B. and L.H. Toledo-Pereyra . Caspase-independent programmed cell death following ischemic stroke. J. Invest. Surg. 21: 141–147, 2008. Crossref, Medline, ISIGoogle Scholar
    • Chung, A.S. and N. Ferrara . Developmental and pathological angiogenesis. Annu. Rev. Cell. Dev. Biol. 27: 563–584, 2011. Crossref, Medline, ISIGoogle Scholar
    • Cui, Y., P. Lu, G. Song, Q. Liu, D. Zhu and X. Liu . Involvement of PI3K/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. Food Chem. Toxicol. 92: 26–37, 2016. Crossref, Medline, ISIGoogle Scholar
    • Du, Y., Z. Lv, D. Sun, Y. Li, L. Sun and J. Zhou . Physcion 8-O-β-glucopyranoside exerts anti-tumor activity against non-small cell lung cancer by targeting PPARγ. Anat. Rec. (Hoboken) 302: 785–793, 2019. Crossref, MedlineGoogle Scholar
    • Dynan, W.S. and R. Tjian . Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 32: 669–680, 1983. Crossref, Medline, ISIGoogle Scholar
    • Fu, J.M., J. Zhou, J. Shi, J.S. Xie, L. Huang, A.Y. Yip, W.T. Loo, L.W. Chow and E.L. Ng . Emodin affects ERCC1 expression in breast cancer cells. J. Transl. Med. 10(Suppl 1): S7, 2012. Crossref, Medline, ISIGoogle Scholar
    • Fu, Z.Y., X. Han and H.Y. Huang . Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells. Chin. Med. J. (Engl.) 120: 1710–1715, 2007. Crossref, Medline, ISIGoogle Scholar
    • Gao, F., W. Liu, Q. Guo, Y. Bai, H. Yang and H. Chen . Physcion blocks cell cycle and induces apoptosis in human B cell precursor acute lymphoblastic leukemia cells by downregulating HOXA5. Biomed. Pharmacother. 94: 850–857, 2017. Crossref, Medline, ISIGoogle Scholar
    • Gentles, A.J., A.M. Newman, C.L. Liu, S.V. Bratman, W. Feng, D. Kim, V.S. Nair, Y. Xu, A. Khuong, C.D. Hoang, M. Diehn, R.B. West, S.K. Plevritis and A.A. Alizadeh . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21: 938–945, 2015. Crossref, Medline, ISIGoogle Scholar
    • Ghimire, G.P., N. Koirala, R.P. Pandey, H.J. Jung and J.K. Sohng . Modification of emodin and aloe-emodin by glycosylation in engineered Escherihia coli. World J. Microbiol. Biotechnol. 31: 611–619, 2015. Crossref, Medline, ISIGoogle Scholar
    • Grivennikov, S.I. and M. Karin . Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11–19, 2010. Crossref, Medline, ISIGoogle Scholar
    • Guo, J., W. Li, H. Shi, X. Xie, L. Li, H. Tang, M. Wu, Y. Kong, L. Yang, J. Gao, P. Liu, W. Wei and X. Xie . Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol. Cell. Biochem. 382: 103–111, 2013. Crossref, Medline, ISIGoogle Scholar
    • Guo, Q., Y. Chen, B. Zhang, M. Kang, Q. Xie and Y. Wu . Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem. Pharmacol. 77: 1674–1683, 2009. Crossref, Medline, ISIGoogle Scholar
    • Han, Y.M., S.K. Lee, D.G. Jeong, S.E. Ryu, D.C. Han, D.K. Kim and B.M. Kwon . Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity. Bioorg. Med. Chem. Lett. 22: 323–326, 2012. Crossref, Medline, ISIGoogle Scholar
    • Han, Y.T., X.H. Chen, H. Gao, J.L. Ye and C.B. Wang . Physcion inhibits the metastatic potential of human colorectal cancer SW620 cells in vitro by suppressing the transcription factor SOX2. Acta Pharmacol. Sin. 37: 264–275, 2016. Crossref, Medline, ISIGoogle Scholar
    • Harshita, M.A., Barkat, S.S., Das, F.H. Pottoo, S. Beg and Z. Rahman . Lipid-based nanosystem as intelligent carriers for versatile drug delivery applications. Curr. Pharm. Des. 26: 1167–1180, 2020. Crossref, Medline, ISIGoogle Scholar
    • Hasnain, M.S., M.N. Javed, M.S. Alam, P. Rishishwar, S. Rishishwar, S. Ali, A.K. Nayak and S. Beg . Purple heart plant leaves extract-mediated silver nanoparticle synthesis: Optimization by Box-Behnken design. Mater. Sci. Eng. C, Mater. Biol. Appl. 99: 1105–1114, 2019. Crossref, Medline, ISIGoogle Scholar
    • He, L., J.J. Bi, Q. Guo, Y. Yu and X.F. Ye . Effects of emodin extracted from Chinese herbs on proliferation of non-small cell lung cancer and underlying mechanisms. Asian Pac. J. Cancer Prev. 13: 1505–1510, 2012. Crossref, MedlineGoogle Scholar
    • Hintzpeter, J., J.M. Seliger, J. Hofman, H.J. Martin, V. Wsol and E. Maser . Inhibition of human anthracycline reductases by emodin - a possible remedy for anthracycline resistance. Toxicol. Appl. Pharmacol. 293: 21–29, 2016. Crossref, Medline, ISIGoogle Scholar
    • Höhn, P., C. Braumann, M. Freiburger, G. Koplin, W. Dubiel and A.M. Luu . Anti-tumorigenic effects of emodin and its homologue BTB14431 on vascularized colonic cancer in a rat model. Asian Pac. J. Cancer Prev. 21: 205–210, 2020. Crossref, MedlineGoogle Scholar
    • Hong, S.J., J.T. Kim, S.J. Kim, N.C. Cho, K. Kim, S. Lee, Y.G. Suh, K.C. Cho, K.P. Kim and Y.J. Surh . An electrophilic deguelin analogue inhibits STAT3 signaling in H-ras-transformed human mammary epithelial cells: The cysteine 259 residue as a potential target. Biomedicines 8: 407, 2020. Crossref, Medline, ISIGoogle Scholar
    • Hou, H., D. Li, D. Cheng, L. Li, Y. Liu and Y. Zhou . Cellular redox status regulates emodin-induced radiosensitization of nasopharyngeal carcinoma cells in vitro and in vivo. J. Pharm. (Cairo) 2013: 218297, 2013. MedlineGoogle Scholar
    • Hsu, C.M., Y.A. Hsu, Y. Tsai, F.K. Shieh, S.H. Huang, L. Wan and F.J. Tsai . Emodin inhibits the growth of hepatoma cells: Finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells. Biochem. Biophys. Res. Commun. 392: 473–478, 2010. Crossref, Medline, ISIGoogle Scholar
    • Huang, P.H., C.Y. Huang, M.C. Chen, Y.T. Lee, C.H. Yue, H.Y. Wang and H. Lin . Emodin and aloe-emodin suppress breast cancer cell proliferation through ER α inhibition. Evid.-based Complement. Alternat. Med. 2013: 376123, 2013. Crossref, Medline, ISIGoogle Scholar
    • Huang, Q., H.M. Shen and C.N. Ong . Emodin inhibits tumor cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway. Cell. Mol. Life Sci. 62: 1167–1175, 2005. Crossref, Medline, ISIGoogle Scholar
    • Huang, Q., H.M. Shen, G. Shui, M.R. Wenk and C.N. Ong . Emodin inhibits tumor cell adhesion through disruption of the membrane lipid raft-associated integrin signaling pathway. Cancer Res. 66: 5807–5815, 2006. Crossref, Medline, ISIGoogle Scholar
    • Huang, X.Z., J. Wang, C. Huang, Y.Y. Chen, G.Y. Shi, Q.S. Hu and J. Yi . Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: The mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol. Ther. 7: 468–475, 2008. Crossref, Medline, ISIGoogle Scholar
    • Huang, Z., G. Chen and P. Shi . Effects of emodin on the gene expression profiling of human breast carcinoma cells. Cancer Detect. Prev. 32: 286–291, 2009. Crossref, MedlineGoogle Scholar
    • Hwang, S.Y., K. Heo, J.S. Kim, J.W. Im, S.M. Lee, M. Cho, D.H. Kang, J. Heo, J.W. Lee, C.W. Choi and K. Yang . Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. Oncol. Rep. 33: 1691–1698, 2015. Crossref, Medline, ISIGoogle Scholar
    • Jänicke, P., C. Lennicke, A. Meister, B. Seliger, L.A. Wessjohann and G.N. Kaluđerović . Fluorescent spherical mesoporous silica nanoparticles loaded with emodin: synthesis, cellular uptake and anticancer activity. Mater. Sci. Eng. C, Mater. Biol. Appl. 119: 111619, 2021. Crossref, Medline, ISIGoogle Scholar
    • Jelassi, B., M. Anchelin, J. Chamouton, M.L. Cayuela, L. Clarysse, J. Li, J. Goré, L.H. Jiang and S. Roger . Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis 34: 1487–1496, 2013. Crossref, Medline, ISIGoogle Scholar
    • Ji, X., Y. Bosse, M.T. Landi, J. Gui, X. Xiao, D. Qian, P. Joubert, M. Lamontagne, Y. Li, I. Gorlov, M. de Biasi, Y. Han, O. Gorlova, R.J. Hung, X. Wu, J. McKay, X. Zong, R. Carreras-Torres, D.C. Christiani, N. Caporaso, M. Johansson, G. Liu, S.E. Bojesen, L. Le Marchand, D. Albanes, H. Bickeboller, M.C. Aldrich, W.S. Bush, A. Tardon, G. Rennert, C. Chen, M.D. Teare, J.K. Field, L.A. Kiemeney, P. Lazarus, A. Haugen, S. Lam, M.B. Schabath, A.S. Andrew, H. Shen, Y.C. Hong, J.M. Yuan, P.A. Bertazzi, A.C. Pesatori, Y. Ye, N. Diao, L. Su, R. Zhang, Y. Brhane, N. Leighl, J.S. Johansen, A. Mellemgaard, W. Saliba, C. Haiman, L. Wilkens, A. Fernandez-Somoano, G. Fernandez-Tardon, E. van der Heijden, J.H. Kim, J. Dai, Z. Hu, M.P.A. Davies, M.W. Marcus, H. Brunnstrom, J. Manjer, O. Melander, D.C. Muller, K. Overvad, A. Trichopoulou, R. Tumino, J. Doherty, G.E. Goodman, A. Cox, F. Taylor, P. Woll, I. Bruske, J. Manz, T. Muley, A. Risch, A. Rosenberger, K. Grankvist, M. Johansson, F. Shepherd, M.S. Tsao, S.M. Arnold, E.B. Haura, C. Bolca, I. Holcatova, V. Janout, M. Kontic, J. Lissowska, A. Mukeria, S. Ognjanovic, T.M. Orlowski, G. Scelo, B. Swiat kowska, D. Zaridze, P. Bakke, V. Skaug, S. Zienolddiny, E.J. Duell, L.M. Butler, W.P. Koh, Y.T. Gao, R. Houlston, J. McLaughlin, V. Stevens, D.C. Nickle, M. Obeidat, W. Timens, B. Zhu, L. Song, M.S. Artigas, M.D. Tobin, L.V. Wain, F. Gu, J. Byun, A. Kamal, D. Zhu, R.F. Tyndale, W.Q. Wei, S. Chanock, P. Brennan and C.I. Amos . Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat. Commun. 9: 3221, 2018. Crossref, Medline, ISIGoogle Scholar
    • Jia, X., F. Yu, J. Wang, S. Iwanowycz, F. Saaoud, Y. Wang, J. Hu, Q. Wang and D. Fan . Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res. Treat. 148: 291–302, 2014. Crossref, Medline, ISIGoogle Scholar
    • Karin, M., Y. Cao, F.R. Greten and Z.W. Li . NF-kappaB in cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 2: 301–310, 2002. Crossref, Medline, ISIGoogle Scholar
    • Karin, M. and A. Lin . NF-kappaB at the crossroads of life and death. Nat. Immunol. 3: 221–227, 2002. Crossref, Medline, ISIGoogle Scholar
    • Khan, H., W. Jia, Z. Yu, T. Zaib, J. Feng, Y. Jiang, H. Song, Y. Bai, B. Yang and H. Feng . Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2. Biomed. Pharmacother. 128: 110244, 2020. Crossref, Medline, ISIGoogle Scholar
    • Kim, J., J.S. Lee, J. Jung, I. Lim, J.Y. Lee and M.J. Park . Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells. Stem Cells Dev. 24: 284–295, 2015. Crossref, Medline, ISIGoogle Scholar
    • Kim, M.S., M.J. Park, S.J. Kim, C.H. Lee, H. Yoo, S.H. Shin, E.S. Song and S.H. Lee . Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells. Int. J. Oncol. 27: 839–846, 2005. Medline, ISIGoogle Scholar
    • Ko, J.C., Y.J. Su, S.T. Lin, J.Y. Jhan, S.C. Ciou, C.M. Cheng, Y.F. Chiu, Y.H. Kuo, M.S. Tsai and Y.W. Lin . Emodin enhances cisplatin-induced cytotoxicity via downregulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 69: 155–164, 2010. Crossref, Medline, ISIGoogle Scholar
    • Ko, J.C., Y.J. Su, S.T. Lin, J.Y. Jhan, S.C. Ciou, C.M. Cheng and Y.W. Lin . Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem. Pharmacol. 79: 655–664, 2010. Crossref, Medline, ISIGoogle Scholar
    • Ko, J.C., M.S. Tsai, Y.H. Kuo, Y.F. Chiu, S.H. Weng, Y.C. Su and Y.W. Lin . Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine. Biochem. Pharmacol. 81: 680–690, 2011. Crossref, Medline, ISIGoogle Scholar
    • Kwak, H.J., M.J. Park, C.M. Park, S.I. Moon, D.H. Yoo, H.C. Lee, S.H. Lee, M.S. Kim, H.W. Lee, W.S. Shin, I.C. Park, C.H. Rhee and S.I. Hong . Emodin inhibits vascular endothelial growth factor-a-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int. J. Cancer 118: 2711–2720, 2006. Crossref, Medline, ISIGoogle Scholar
    • Li, J., P. Liu, H. Mao, A. Wanga and X. Zhang . Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol. Rep. 21: 1605–1610, 2009. Medline, ISIGoogle Scholar
    • Li, Q., J. Gao, X. Pang, A. Chen and Y. Wang . Molecular mechanisms of action of emodin: As an anti-cardiovascular disease drug. Front. Pharmacol. 11: 559607, 2020. Crossref, Medline, ISIGoogle Scholar
    • Li, T., W. Si, J. Zhu, L. Yin and C. Zhong . Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway. Am. J. Transl. Res. 12: 1851–1861, 2020. Medline, ISIGoogle Scholar
    • Li, W., F. Li, Y. Zhu and D. Song . RETRACTED: Physcion 8-O-β-glucopyranosideregulates cell cycle, apoptosis, and invasion in glioblastoma cells through modulating Skp2. Biomed. Pharmacother. 95: 1129–1138, 2017. Crossref, Medline, ISIGoogle Scholar
    • Li, W.Y., R.Y. Chan, P.H. Yu and S.W. Chan . Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes. Pharm. Biol. 51: 1175–1181, 2013. Crossref, Medline, ISIGoogle Scholar
    • Li, X.X., Y. Dong, W. Wang, H.L. Wang, Y.Y. Chen, G.Y. Shi, J. Yi and J. Wang . Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev. 22: 554–566, 2013. Crossref, Medline, ISIGoogle Scholar
    • Lin, M.L., Y.C. Lu, H.L. Su, H.T. Lin, C.C. Lee, S.E. Kang, T.C. Lai, J.G. Chung and S.S. Chen . Destabilization of CARP mRNAs by aloe-emodin contributes to caspase-8-mediated p53-independent apoptosis of human carcinoma cells. J. Cell. Biochem. 112: 1176–1191, 2011. Crossref, Medline, ISIGoogle Scholar
    • Lin, S.Y., Lai, W.W. Lai, C.C. Ho, F.S. Yu, G.W. Chen, J.S. Yang, K.C. Liu, M.L. Lin, P.P. Wu, M.J. Fan and J.G. Chung . Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. Anticancer Res. 29: 327–335, 2009. Medline, ISIGoogle Scholar
    • Lin, S.Z., W.T. Wei, H. Chen, K.J. Chen, H.F. Tong, Z.H. Wang, Z.L. Ni, H.B. Liu, H.C. Guo and D.L. Liu . Antitumor activity of emodin against pancreatic cancer depends on its dual role: Promotion of apoptosis and suppression of angiogenesis. PLoS One 7: e42146, 2012. Crossref, Medline, ISIGoogle Scholar
    • Lin, S.Z., J.B. Xu, X. Ji, H. Chen, H.T. Xu, P. Hu, L. Chen, J.Q. Guo, M.Y. Chen, D. Lu, Z.H. Wang and H.F. Tong . Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-beta/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs. Mol. Med. Rep. 12: 5865–5871, 2015. Crossref, Medline, ISIGoogle Scholar
    • Liu, A., H. Chen, H. Tong, S. Ye, M. Qiu, Z. Wang, W. Tan, J. Liu and S. Lin . Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB. Mol. Med. Rep. 4: 221–227, 2011. Medline, ISIGoogle Scholar
    • Liu, A., H. Chen, W. Wei, S. Ye, W. Liao, J. Gong, Z. Jiang, L. Wang and S. Lin . Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol. Rep. 26: 81–89, 2011. Medline, ISIGoogle Scholar
    • Liu, A., Y.S. Hu, Z.H. Wang, L.L. Tang, P.Y. Ke and S.Z. Lin . Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine. Yao. Xue. Xue. Bao. 46: 146–152, 2011. MedlineGoogle Scholar
    • Liu, B., B. Yuan, L. Zhang, W. Mu and C. Wang . ROS/p38/p53/Puma signaling pathway is involved in emodin-induced apoptosis of human colorectal cancer cells. Int. J. Clin. Exp. Med. 8: 15413–15422, 2015. Medline, ISIGoogle Scholar
    • Liu, C., L. Chen, W. Wang, D. Qin, C. Jia, M. Yuan, H. Wang, Y. Guo, J. Zhu, Y. Zhou, H. Zhao and T. Liu . Emodin suppresses the migration and invasion of melanoma cells. Biol. Pharm. Bull. 44: 771–779, 2021. Crossref, Medline, ISIGoogle Scholar
    • Liu, H., Y. Zhuang, P. Wang, T. Zou, M. Lan, L. Li, F. Liu, T. Cai and Y. Cai . Polymeric lipid hybrid nanoparticles as a delivery system enhance the antitumor effect of emodin in vitro and in vivo. J. Pharm. Sci. 110: 2986–2996, 2021. Crossref, Medline, ISIGoogle Scholar
    • Liu, D.L., H. Bu, H. Li, H. Chen, H.C. Guo, Z.H. Wang, H.F. Tong, Z.L. Ni, H.B. Liu and S.Z. Lin . Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro. Int. J. Oncol. 40: 1049–1057, 2012. Crossref, Medline, ISIGoogle Scholar
    • Liu, H., M. Gao, H. Xu, X. Guan, L. Lv, S. Deng, C. Zhang and Y. Tian . A promising emodin-loaded poly (lactic-co-glycolic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles for liver cancer therapy. Pharm. Res. 33: 217–236, 2016. Crossref, Medline, ISIGoogle Scholar
    • Lu, H.F., K.C. Lai, S.C. Hsu, H.J. Lin, C.L. Kuo, C.L. Liao, J.S. Yang and J.G. Chung . Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem. Res. 34: 1575–1583, 2009. Crossref, Medline, ISIGoogle Scholar
    • Lu, J., Y. Xu, Z. Zhao, X. Ke, X. Wei, J. Kang, X. Zong, H. Mao and P. Liu . Emodin suppresses proliferation, migration and invasion in ovarian cancer cells by down regulating ILK in vitro and in vivo. OncoTargets Ther. 10: 3579–3589, 2017. Crossref, Medline, ISIGoogle Scholar
    • Ma, J., H. Lu, S. Wang, B. Chen, Z. Liu, X. Ke, T. Liu and J. Fu . The anthraquinone derivative emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer. Int. J. Oncol. 46: 1619–1628, 2015. Crossref, Medline, ISIGoogle Scholar
    • Ma, J., J. Yang, C. Wang, N. Zhang, Y. Dong, C. Wang, Y. Wang and X. Lin . Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation. Biomed. Res. Int. 2014: 107671, 2014. Crossref, Medline, ISIGoogle Scholar
    • Ma, L., K. Chen, K. Jiang, G. Deng, P. Jiang, J. Shao, and Z. Yu . Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1. Int J. Clin. Exp. Pathol. 10: 9452–9459, 2017. Medline, ISIGoogle Scholar
    • Ma, L., Y. Yang, Z. Yin, M. Liu, L. Wang, L. Chen, L. Zhu and H. Yang . Emodin suppresses the nasopharyngeal carcinoma cells by targeting the chloride channels. Biomed. Pharmacother. 90: 615–625, 2017. Crossref, Medline, ISIGoogle Scholar
    • Ma, Q., Y. Ding, Z. Wu and Y. Li . Antitumor effects of emodin in CACO-2 human colon carcinoma cells are mediated via apoptosis, cell cycle arrest and downregulation of PI3K/AKT signalling pathway. J. BUON 23: 587–591, 2018. Medline, ISIGoogle Scholar
    • Manimaran, A., R. Buddhan and S. Manoharan . Emodin downregulates cell proliferation markers during DMBA–induced oral carcinogenesis in Golden Syrian hamsters. Afr. J. Tradit. Complement. Altern. Med. 14: 83–91, 2017. Crossref, MedlineGoogle Scholar
    • Manu, K.A., M.K. Shanmugam, T.H. Ong, A. Subramaniam, K.S. Siveen, E. Perumal, R.P. Samy, P. Bist, L.H. Lim, A.P. Kumar, K.M. Hui and G. Sethi . Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS One 8: e57015, 2013. Crossref, Medline, ISIGoogle Scholar
    • Masaldan, S. and V.V. Iyer . Exploration of effects of emodin in selected cancer cell lines: Enhanced growth inhibition by ascorbic acid and regulation of LRP1 and AR under hypoxia-like conditions. J. Appl. Toxicol. 34: 95–104, 2014. Crossref, Medline, ISIGoogle Scholar
    • Morad, S.A. and M.C. Cabot . Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer. 13: 51–65, 2013. Crossref, Medline, ISIGoogle Scholar
    • Mumtaz, S.M., G. Bhardwaj, S. Goswami, R.K. Tonk, R.K. Goyal, T. Abu-Izneid and F.H. Pottoo . Management of glioblastoma multiforme by phytochemicals: applications of nanoparticle-based targeted drug delivery system. Curr. Drug Targets 22: 429–442, 2021. Crossref, Medline, ISIGoogle Scholar
    • Muto, A., M. Hori, Y. Sasaki, A. Saitoh, I. Yasuda, T. Maekawa, T. Uchida, K. Asakura, T. Nakazato, T. Kaneda, M. Kizaki, Y. Ikeda and T. Yoshida . Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol. Cancer Ther. 6: 987–994, 2007. Crossref, Medline, ISIGoogle Scholar
    • Obiorah, I., S. Sengupta, P. Fan and V.C. Jordan . Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death. Br. J. Cancer 115: e10, 2016. Crossref, Medline, ISIGoogle Scholar
    • Olsen, B.B., M. Bjørling-Poulsen and B. Guerra . Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: A study on its mechanism of action. Int. J. Biochem. Cell. Biol. 39: 227–237, 2007. Crossref, Medline, ISIGoogle Scholar
    • Pan, X.P., C. Wang, Y. Li and L.H. Huang . Physcion induces apoptosis through triggering endoplasmic reticulum stress in hepatocellular carcinoma. Biomed. Pharmacother. 99: 894–903, 2018. Crossref, Medline, ISIGoogle Scholar
    • Pang, M.J., Z. Yang, X.L. Zhang, Z.F. Liu, J. Fan and H.Y. Zhang . Physcion, a naturally occurring anthraquinone derivative, induces apoptosis and autophagy in human nasopharyngeal carcinoma. Acta Pharmacol. Sin. 37: 1623–1640, 2016. Crossref, Medline, ISIGoogle Scholar
    • Pooja, T. and D. Karunagaran . Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620. Eur. J. Pharmacol. 742: 55–64, 2014. Crossref, Medline, ISIGoogle Scholar
    • Pottoo, F.H., M.A. Barkat, Harshita, M.A. Ansari, M.N. Javed, Q.M. Sajid Jamal and M.A. Kamal . Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Semin. Cancer Biol. 69: 100–108, 2021. Crossref, Medline, ISIGoogle Scholar
    • Pourhajibagher, M., S. Etemad-Moghadam, M. Alaeddini and A. Bahador . Modulation of the triggered apoptosis by nano emodin transfersome-mediated sonodynamic therapy on head and neck squamous cell carcinoma cell lines. Photodiagnosis Photodyn. Ther. 34: 102253, 2021. Crossref, Medline, ISIGoogle Scholar
    • Qaed, E., J. Wang, M. Almoiliqy, Y. Song, W. Liu, P. Chu, S. Alademi, M. Alademi, H. Li, M. Alshwmi, M. Al-Azab, A. Ahsan, S. Mahdi, G. Han, M. Niu, A. Ali, A. Shopit, H. Wang, X. Li, A. Qaid, X. Ma, T. Li, J. Peng, J. Ma, J. Zhang and Z. Tang . Phosphocreatine improves cardiac dysfunction by normalizing mitochondrial respiratory function through JAK2/STAT3 signaling pathway. Oxid. Med. Cell. Longev. 2019: 6521218, 2019. Medline, ISIGoogle Scholar
    • Qu, W., Y. Wang, Q. Wu, J. Liu and D. Hao . Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1. Int. J. Clin. Exp. Med. 8: 15054–15064, 2015. Medline, ISIGoogle Scholar
    • Rajitha, B., A. Belalcazar, G.P. Nagaraju, W.L. Shaib, J.P. Snyder, M. Shoji, S. Pattnaik, A. Alam and B.F. El-Rayes . Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. Cancer Lett. 373: 227–233, 2016. Crossref, Medline, ISIGoogle Scholar
    • Sakalli-Tecim, E., P. Uyar-Arpaci and N.T. Guray . Identification of potential therapeutic genes and pathways in phytoestrogen emodin treated breast cancer cell lines via network biology approaches. Nutr. Cancer 74: 1–13, 2021. Medline, ISIGoogle Scholar
    • Sánchez, M., E. González-Burgos, I. Iglesias and M.P. Gómez-Serranillos . Pharmacological update properties of aloe vera and its major active constituents. Molecules 25: 1324, 2020. Crossref, Medline, ISIGoogle Scholar
    • Shanmugam, M.K., S. Warrier, A.P. Kumar, G. Sethi and F. Arfuso . Potential role of natural compounds as anti-angiogenic agents in cancer. Curr. Vasc. Pharmacol. 15: 503–519, 2017. Crossref, Medline, ISIGoogle Scholar
    • Shi, G.H. and L. Zhou . Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6-mediated pathways in vivo and in vitro. Mol. Med. Rep. 18: 5191–5197, 2018. Medline, ISIGoogle Scholar
    • Shrimali, D., M.K. Shanmugam, A.P. Kumar, J. Zhang, B.K. Tan, K.S. Ahn and G. Sethi . Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341: 139–149, 2013. Crossref, Medline, ISIGoogle Scholar
    • Singh, K.B. and S.K. Trigun . Apoptosis of dalton’s lymphoma due to in vivo treatment with emodin is associated with modulations of hydrogen peroxide metabolizing antioxidant enzymes. Cell. Biochem. Biophys. 67: 439–449, 2013. Crossref, Medline, ISIGoogle Scholar
    • Song, S.Z., S. Lin, J.N. Liu, M.B. Zhang, Y.T. Du, D.D. Zhang, W.H. Xu and H.B. Wang . Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway. J. Cell. Physiol. 234: 18587–18601, 2019. Crossref, Medline, ISIGoogle Scholar
    • Su, Y.J., M.S. Tsai, Y.H. Kuo, Y.F. Chiu, C.M. Cheng, S.T. Lin and Y.W. Lin . Role of Rad51 downregulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin c-induced synergistic cytotoxicity in human non-small-cell lung cancer cells. Mol. Pharmacol. 77: 633–643, 2010. Crossref, Medline, ISIGoogle Scholar
    • Subramaniam, A., S.Y. Loo, P. Rajendran, K.A. Manu, E. Perumal, F. Li, M.K. Shanmugam, K.S. Siveen, J.I. Park, K.S. Ahn, K.M. Hui, A.P. Kumar and G. Sethi . An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis 18: 1175–1187, 2013a. Crossref, Medline, ISIGoogle Scholar
    • Subramaniam, A., M.K. Shanmugam, T.H. Ong, F. Li, E. Perumal, L. Chen, S. Vali, T. Abbasi, S. Kapoor, K.S. Ahn, A.P. Kumar, K.M. Hui and G. Sethi . Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br. J. Pharmacol. 170: 807–821, 2013b. Crossref, Medline, ISIGoogle Scholar
    • Sui, J.Q., K.P. Xie, W. Zou and M.J. Xie . Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway. Asian Pac. J. Cancer Prev. 15: 6247–6251, 2014. Crossref, MedlineGoogle Scholar
    • Sun, Y., X. Wang, Q. Zhou, Y. Lu, H. Zhang, Q. Chen, M. Zhao and S. Su . Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol. Rep. 33: 338–346, 2015. Crossref, Medline, ISIGoogle Scholar
    • Sun, Z.H. and P. Bu . Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line. Exp. Ther. Med. 3: 1077–1081, 2012. Crossref, Medline, ISIGoogle Scholar
    • Szakács, G., J.K. Paterson, J.A. Ludwig, C. Booth-Genthe and M.M. Gottesman . Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5: 219–234, 2006. Crossref, Medline, ISIGoogle Scholar
    • Tan, W., J. Lu, M. Huang, Y. Li, M. Chen, G. Wu, J. Gong, Z. Zhong, Z. Xu, Y. Dang, J. Guo, X. Chen and Y. Wang . Anti-cancer natural products isolated from chinese medicinal herbs. Chin. Med. 6: 27, 2011. Crossref, Medline, ISIGoogle Scholar
    • Tang, Q., J. Wu, F. Zheng, S.S. Hann and Y. Chen . Emodin increases expression of insulin-like growth factor binding protein 1 through activation of MEK/ERK/AMPKα and interaction of PPARγ and Sp1 in lung cancer. Cell. Physiol. Biochem. 41: 339–357, 2017. Crossref, MedlineGoogle Scholar
    • Tang, Q., S. Zhao, J. Wu, F. Zheng, L. Yang, J. Hu and S.S. Hann . Inhibition of integrin-linked kinase expression by emodin through crosstalk of AMPKα and ERK1/2 signaling and reciprocal interplay of Sp1 and c-Jun. Cell. Signal. 27: 1469–1477, 2015. Crossref, Medline, ISIGoogle Scholar
    • Tang, S.H., H.S. Huang, H.U. Wu, Y.T. Tsai, M.J. Chuang, C.P. Yu, S.M. Huang, G.H. Sun, S.Y. Chang, P.W. Hsiao, D.S. Yu and T.L. Cha . Pharmacologic downregulation of EZH2 suppresses bladder cancer in vitro and in vivo. Oncotarget 5: 10342–10355, 2014. Crossref, MedlineGoogle Scholar
    • Thacker, P.C. and D. Karunagaran . Curcumin and emodin downregulate TGF-β signaling pathway in human cervical cancer cells. PLoS One 10: e0120045, 2015. Crossref, Medline, ISIGoogle Scholar
    • Wahi, D., D. Soni and A. Grover . A double-edged sword: the anti-cancer effects of emodin by inhibiting the redox-protective protein MTH1 and augmenting ROS in NSCLC. J. Cancer 12: 652–681, 2021. Crossref, Medline, ISIGoogle Scholar
    • Wang, B., L. Chen, Y. Sun, Y. Zhu, Z. Sun, T. An, Y. Li, Y. Lin, D. Fan and Q. Wang . Development of phenylboronic acid-functionalized nanoparticles for emodin delivery. J. Mater. Chem. B 3: 3840–3847, 2015. Crossref, Medline, ISIGoogle Scholar
    • Wang, L.N., Z.J. Li, Y.M. Xi, C. Chen, T. Ma, L. Zhao, M.F. Jia, M. Li, H. Zhang and C.X. Liu . Effect of emodin combined with AZT on the proliferation and the expression of BCL-2, NF-κB, TGF-β in the leukemia stem cells-KG-1a cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 23: 1265–1271, 2015. MedlineGoogle Scholar
    • Wang, Q., Y. Jiang, R. Guo, R. Lv, T. Liu, H. Wei, H. Ming and X. Tian . Physcion 8-O-β-glucopyranoside suppresses tumor growth of hepatocellular carcinoma by downregulating PIM1. Biomed. Pharmacother. 92: 451–458, 2017. Crossref, Medline, ISIGoogle Scholar
    • Wang, Q.J., X.B. Cai, M.H. Liu, H. Hu, X.J. Tan and X.B. Jing . Apoptosis induced by emodin is associated with alterations of intracellular acidification and reactive oxygen species in EC-109 cells. Biochem. Cell. Biol. 88: 767–774, 2010. Crossref, Medline, ISIGoogle Scholar
    • Wang, W., Y.P. Sun, X.Z. Huang, M. He, Y.Y. Chen, G.Y. Shi, H. Li, J. Yi and J. Wang . Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem. Pharmacol. 79: 1134–1140, 2010. Crossref, Medline, ISIGoogle Scholar
    • Wang, S., T. Chen, R. Chen, Y. Hu, M. Chen and Y. Wang . Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int. J. Pharm. 430: 238–246, 2012. Crossref, Medline, ISIGoogle Scholar
    • Wang, W., Z. Bai, F. Zhang, C. Wang, Y. Yuan and J. Shao . Synthesis and biological activity evaluation of emodin quaternary ammonium salt derivatives as potential anticancer agents. Eur. J. Med. Chem. 56: 320–331, 2012. Crossref, Medline, ISIGoogle Scholar
    • Wang, Y., H. Yu, J. Zhang, X. Ge, J. Gao, Y. Zhang and G. Lou . Anti-tumor effect of emodin on gynecological cancer cells. Cell. Oncol. (Dordr.) 38: 353–363, 2015. Crossref, Medline, ISIGoogle Scholar
    • Wang, Z., H. Chen, J. Chen, Z. Hong, Y. Liao, Q. Zhang and H. Tong . Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway. Cancer Manag. Res. 11: 8463–8473, 2019. Crossref, Medline, ISIGoogle Scholar
    • Wang, Z., T. Tang, S. Wang, T. Cai, H. Tao, Q. Zhang, S. Qi and Z. Qi . Aloin inhibits the proliferation and migration of gastric cancer cells by regulating NOX2-ROS-mediated pro-survival signal pathways. Drug. Des. Devel. Ther. 14: 145–155, 2020. Crossref, Medline, ISIGoogle Scholar
    • Way, T.D., J.T. Huang, C.H. Chou, C.H. Huang, M.H. Yang and C.T. Ho . Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the β-catenin and Akt pathways. Eur. J. Cancer 50: 366–378, 2014. Crossref, Medline, ISIGoogle Scholar
    • Wei, W.T., H. Chen, Z.L. Ni, H.B. Liu, H.F. Tong, L. Fan, A. Liu, M.X. Qiu, D.L. Liu, H.C. Guo, Z.H. Wang and S.Z. Lin . Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from rheum officinale baill, against pancreatic cancer in mice via inhibition of Akt activation. Int. J. Oncol. 39: 1381–1390, 2011. Medline, ISIGoogle Scholar
    • Wen-Feng, W., Z. Feng-Sen, Z. Wen-Na, B. Ze-Dong, Y. Hui-Jun, S. Jing-Wei and Y. Yao-Feng . The synthesis, structural study and anticancer activity evaluation of emodin derivatives containing conjugative groups. Med. Chem. 9: 545–552, 2013. Crossref, Medline, ISIGoogle Scholar
    • Wu, C.C., M.S. Chen, Y.J. Cheng, Y.C. Ko, S.F. Lin, I.M. Chiu, and J.Y. Chen . Emodin inhibits EBV reactivation and represses NPC tumorigenesis. Cancers (Basel) 11: 1795, 2019. Crossref, Medline, ISIGoogle Scholar
    • Wu, L., F. Zhang, S.Z. Zheng, Y. Lu and B.C. Cai . Effect of emodin in attenuating endoplasmic reticulum stress of pancreatic acinar AR42J cells. Zhongguo Zhong Yao Za Zhi 40: 501–505, 2015. MedlineGoogle Scholar
    • Xing, J.Y., G.P. Song, J.P. Deng, L.Z. Jiang, P. Xiong, B.J. Yang and S.S. Liu . Antitumor effects and mechanism of novel emodin rhamnoside derivatives against human cancer cells in vitro. PLoS One 10: e0144781, 2015. Crossref, Medline, ISIGoogle Scholar
    • Xu, Y., M. Shen, Y. Li, Y. Sun, Y. Teng, Y. Wang and Y. Duan . The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. Oncotarget 7: 20890–20901, 2016. Crossref, MedlineGoogle Scholar
    • Xue, H., Y. Chen, X. Cai, L. Zhao, A. He, K. Guo and X. Zheng . The combined effect of survivin-targeted shRNA and emodin on the proliferation and invasion of ovarian cancer cells. Anticancer Drugs 24: 937–944, 2013. Crossref, Medline, ISIGoogle Scholar
    • Yan, Y., X. Su, Y. Liang, J. Zhang, C. Shi, Y. Lu, L. Gu and L. Fu . Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol. Cancer Ther. 7: 1688–1697, 2008. Crossref, Medline, ISIGoogle Scholar
    • Yan, Y.Y., L.W. Fu, W. Zhang, H.S. Ma, C.G. Ma, Y.J. Liang, B.Y. Liu, J.Z. Yu, Q.Z. Wu and Y.M. Dong . Emodin azide methyl anthraquinone derivative induced G0/ G1 arrest in HER2/neu-overexpressing MDA-MB-453 breast cancer cells. J. BUON 19: 650–655, 2014. Medline, ISIGoogle Scholar
    • Yan, Y.Y., L.S. Zheng, X. Zhang, L.K. Chen, S. Singh, F. Wang, J.Y. Zhang, Y.J. Liang, C.L. Dai, L.Q. Gu, M.S. Zeng, T.T. Talele, Z.S. Chen and L.W. Fu . Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. Mol. Pharm. 8: 1687–1697, 2011. Crossref, Medline, ISIGoogle Scholar
    • Yin, J., X. Zhao, X. Chen and G. Shen . Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B. Bioengineered 13: 9548–9563, 2022. Crossref, Medline, ISIGoogle Scholar
    • Ying, J., H. Xu, D. Wu and X. Wu . Emodin induces apoptosis of human osteosarcoma cells via mitochondria- and endoplasmic reticulum stress-related pathways. Int. J. Clin. Exp. Pathol. 8: 12837–12844, 2015. Medline, ISIGoogle Scholar
    • Yu, C.X., X.Q. Zhang, L.D. Kang, P.J. Zhang, W.W. Chen, W.W. Liu, Q.W. Liu and J.Y. Zhang . Emodin induces apoptosis in human prostate cancer cell LNCaP. Asian J. Androl. 10: 625–634, 2008. Crossref, Medline, ISIGoogle Scholar
    • Yu, H., H. Lee, A. Herrmann, R. Buettner and R. Jove . Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer. 14: 736–746, 2014. Crossref, Medline, ISIGoogle Scholar
    • Yu, J.Q., W. Bao and J.C. Lei . Emodin regulates apoptotic pathway in human liver cancer cells. Phytother. Res. 27: 251–257, 2013. Crossref, Medline, ISIGoogle Scholar
    • Yuan, L.Y., C. Chen, H.Y. Chu and Y. Liu . Effects of the combination of emodin and 3'-azido-3'-deoxythymidine on proliferation and apoptosis in leukemia KG-1a cells Transfected with Egr-1 siRNA. Zhongguo. Shi. Yan. Xue. Ye. Xue. Za. Zhi. 23: 386–391, 2015. MedlineGoogle Scholar
    • Zhang, H., L. Chen, H.Q. Bu, Q.J. Yu, D.D. Jiang, F.P. Pan, Y. Wang, D.L. Liu and S.Z. Lin . Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells. Oncol. Rep. 33: 3015–3023, 2015. Crossref, Medline, ISIGoogle Scholar
    • Zhang, J., Z. Hu and Z. Chen . Inhibitory effect of emodin on the growth of cervical cancer in tumor-transplanted mice and underlying mechanism. Xi. Bao. Yu. Fen. Zi. Mian. Yi. Xue. Za. Zhi. 31: 350–354, 2015. MedlineGoogle Scholar
    • Zhang, J.P., H. Zhang, H.B. Wang, Y.X. Li, G.H. Liu, S. Xing, M.Z. Li and M.S. Zeng . Downregulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. J. Transl. Med. 12: 222, 2014. Crossref, Medline, ISIGoogle Scholar
    • Zhang, N., J. Wang, A. Sheng, S. Huang, Y. Tang, S. Ma and G. Hong . Emodin inhibits the proliferation of MCF-7 human breast cancer cells through activation of aryl hydrocarbon receptor (AhR). Front. Pharmacol. 11: 622046, 2020. Crossref, Medline, ISIGoogle Scholar
    • Zhang, Y., W. Pu, M. Bousquenaud, S. Cattin, J. Zaric, L.K. Sun and C. Rüegg . Emodin inhibits inflammation, carcinogenesis, and cancer progression in the AOM/DSS model of colitis-associated intestinal tumorigenesis. Front. Oncol. 10: 564674, 2020. Crossref, Medline, ISIGoogle Scholar
    • Zhang, W., C. Liu, J. Li, Y. Lu, H. Li, J. Zhuang, X. Ren, M. Wang and C. Sun . Tanshinone IIA: New perspective on the anti-tumor mechanism of a traditional natural medicine. Am. J. Chin. Med. 50: 209–239, 2022. Link, ISIGoogle Scholar
    • Zhang, W., H. Chen, D.L. Liu, H. Li, J. Luo, J.H. Zhang, Y. Li, K.J. Chen, H.F. Tong and S.Z. Lin . Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int. J. Oncol. 42: 1189–1196, 2013. Crossref, Medline, ISIGoogle Scholar
    • Zhang, X., C. Y. Chen, T. Zhang and Y. Zhang . Inhibitory effect of emodin on human hepatoma cell line SMMC-7721 and its mechanism. Afr. Health Sci. 15: 97–100, 2015. Crossref, Medline, ISIGoogle Scholar
    • Zhang, X., J. Ding, C. Gou, T. Wen, L. Li, X. Wang, H. Yang, D. Liu, J. Lou, D. Chen, F. Ren and X. Li . Qingchangligan formula attenuates the inflammatory response to protect the liver from acute failure induced by d-galactosamine/lipopolysaccharide in mice. J. Ethnopharmacol. 201: 108–116, 2017. Crossref, Medline, ISIGoogle Scholar
    • Zhang, X.G., G.Y. Ma, F. Kou, W.J. Liu, Q.Y. Sun, G.J. Guo, X.D. Ma, S.J. Guo and J.N. Jian-Ning . Reynoutria japonica from traditional chinese medicine: a source of competitive adenosine deaminase inhibitors for anticancer. Comb. Chem. High Throughput Screen. 22: 113–122, 2019. Crossref, Medline, ISIGoogle Scholar
    • Zhao, D., W. Han, X. Liu, D. Cui and Y. Chen . Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2. Thorac. Cancer 8: 320–327, 2017. Crossref, Medline, ISIGoogle Scholar
    • Zhao, L.M., L.M. Zhang, J.J. Liu, L.J. Wan, Y.Q. Chen, S.Q. Zhang, Z.W. Yan and J.H. Jiang . Synthesis and antitumor activity of conjugates of 5-fluorouracil and Emodin. Eur. J. Med Chem. 47: 255–260, 2012. Crossref, Medline, ISIGoogle Scholar
    • Zhao, X.A., G. Chen, Y. Liu, H. Wu, J. Chen, Y. Xiong, C. Tian, B. Jia, G. Wang, J. Xia, Y. Chen, J. Wang, X. Yan, Z. Zhang, R. Huang and C. Wu . Emodin alleviates liver fibrosis of mice by reducing infiltration of gr1(hi) monocytes. Evid.-based Complem. Altern. Med. eCAM 2018: 5738101, 2018. Medline, ISIGoogle Scholar
    • Zhou, J., G. Li, G. Han, S. Feng, Y. Liu, J. Chen, C. Liu, L. Zhao and F. Jin . Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIP1/RIP3 pathway. Invest. New Drugs 38: 50–59, 2020. Crossref, Medline, ISIGoogle Scholar
    • Zou, G., X. Zhang, L. Wang, X. Li, T. Xie, J. Zhao, J. Yan, L. Wang, H. Ye, S. Jiao, R. Xiang and Y. Shi . Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics 10: 6839–6853, 2020. Crossref, Medline, ISIGoogle Scholar
    Remember to check out the Most Cited Articles!

    Check out our Chinese Medicine Titles today.
    Includes titles by Nobel Winner, Tu You You and more!